ABL Bio and GSK Unite to Break the Brain Barrier in Neurodegenerative Drug Delivery

In a major leap forward for neurodegenerative disease research, ABL Bio has inked a global licensing deal with GSK, granting the pharmaceutical giant access to its proprietary blood-brain barrier (BBB) shuttle platform, Grabody-B. This strategic collaboration is designed to unlock new treatment possibilities for conditions like Alzheimer’s and Parkinson’s by enhancing the brain’s accessibility to promising therapeutic agents—especially antibodies and oligonucleotides that typically struggle to cross the BBB. With an upfront and near-term payment potential of £77.1 million and total milestones reaching up to £2.075 billion, the agreement marks a significant endorsement of ABL Bio’s innovation in BBB-penetrating technologies.

GSK’s SVP of Research Technologies, Christopher Austin, highlighted the urgency: “There is a critical need for new therapeutics to treat neurodegenerative brain diseases… and this partnership reflects our commitment to breakthrough technologies.” Sang Hoon Lee, CEO of ABL Bio, echoed the sentiment, emphasizing the partnership’s potential to accelerate life-changing drug development and strengthen ABL Bio’s leadership in the field. With GSK taking charge of clinical development and commercialization, this alliance aims to usher in a new era of hope for patients suffering from devastating neurological disorders.